Head-to-head · WeighScore
Alan Meds vs NuuVim
The verdict
Too close to call — both grade 71.1/100 (C).
Alan Meds and NuuVim land on the same WeighScore, so neither clears the other on our six graded dimensions. Alan Meds sits one line higher on the board (#99 vs #101) on the underlying tiebreak, but it's a genuine coin-flip — pick on the factors and prices that matter most to you below.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Alan Meds | NuuVim |
|---|---|---|
| WeighScore | 71.1/100 | 71.1/100 |
| Grade | C | C |
| Scorecard rank | #99 | #101 |
| Semaglutide | $158/mo (compounded) | $79/mo (all doses, compounded) |
| Tirzepatide | $295/mo (compounded) | $133/mo (all doses, compounded) |
| Coverage | 46 states | Coverage not published |
| Brand-name access | Compounded only | Yes |
| Oral / sublingual | Yes | Yes |
Graded #99 · C
Strengths
- Aggressively low monthly pricing
- Both semaglutide and tirzepatide available
- Compounded GLP-1 access
- Multiple administration formats
Where it loses points
- Limited public information on program details
Graded #101 · C
Strengths
- Low compounded entry pricing — semaglutide from $79/mo, tirzepatide from $133/mo, flat all-dose pricing
- Both injectable and oral compounded options for semaglutide and tirzepatide (oral access is uncommon)
- LegitScript Certified and HIPAA-compliant
- Two named compounding pharmacy partners (Hallandale Pharmacy and Pharmacy Hub), both vetted in our directory
- Operating legal entity disclosed: NuuVim LLC, Texas governing law
Where it loses points
- No founder, CEO, medical director, or pharmacist-in-charge named
- Refund and cancellation policy not surfaced on the site
- Compounded medications are not FDA-approved
- Doesn't disclose which pharmacy fills which drug or form
- FDA issued this company a warning letter dated 19 March 2025; the letter is public in FDA's warning-letter database
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.